Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for David R Epstein. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at David R Epstein har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
Director | 27.041 | |
US:SGEN / Seagen Inc | CEO, Director | 0 |
US:EVLO / Evelo Biosciences, Inc. | Director | 93.932 |
US:SNTI / Senti Biosciences, Inc. | Director | 123.252 |
US:AXLA / Axcella Health Inc. | Director | 209.756 |
US:RUBY / Rubius Therapeutics, Inc. | Director | 499.762 |
US:US6710051060 / OPY Acquisition Corp. I | Director | 0 |
US:IFF / International Flavors & Fragrances Inc. | Director | 6.397 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af David R Epstein. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb EVLO / Evelo Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EVLO / Evelo Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EVLO / Evelo Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EVLO / Evelo Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SNTI / Senti Biosciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i EVLO / Evelo Biosciences, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SNTI / Senti Biosciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i EVLO / Evelo Biosciences, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af David R Epstein som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-09-04 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
S - Sale | X | -250 | 27.041 | -0,92 | 73,64 | -18.410 | 1.991.299 |
2025-08-05 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
S - Sale | X | -370 | 27.291 | -1,34 | 55,16 | -20.409 | 1.505.372 |
2025-06-04 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
S - Sale | X | -250 | 27.661 | -0,90 | 55,20 | -13.800 | 1.526.887 |
2025-05-22 |
|
4 | TEM |
Tempus AI, Inc.
Class A Comnmon Stock |
A - Award | 1.997 | 27.911 | 7,71 | ||||
2025-05-05 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
S - Sale | X | -370 | 25.914 | -1,41 | 53,50 | -19.795 | 1.386.399 |
2025-03-19 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
S - Sale | X | -990 | 26.284 | -3,63 | 46,83 | -46.362 | 1.230.880 |
2025-03-05 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
S - Sale | X | -250 | 27.274 | -0,91 | 57,52 | -14.380 | 1.568.800 |
2025-02-05 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
S - Sale | X | -370 | 27.524 | -1,33 | 53,31 | -19.725 | 1.467.304 |
2024-12-13 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
S - Sale | X | -620 | 27.894 | -2,17 | 41,81 | -25.922 | 1.166.248 |
2024-06-17 |
|
4 | TEM |
Tempus AI, Inc.
Class A Common Stock |
A - Award | 28.514 | 28.514 | |||||
2023-12-15 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
D - Sale to Issuer | -16.407 | 0 | -100,00 | 229,00 | -3.757.203 | ||
2023-11-13 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
S - Sale | X | -10.620 | 136.598 | -7,21 | 213,01 | -2.262.166 | 29.096.740 |
2023-08-17 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 39.650 | 147.218 | 36,86 | ||||
2022-11-14 |
|
4 | SGEN |
Seagen Inc.
Common Stock |
A - Award | 107.389 | 107.389 | |||||
2022-06-30 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.874 | 93.932 | 3,16 | ||||
2022-06-30 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.053 | 91.058 | 2,31 | ||||
2022-06-10 |
|
4 | SNTI |
Dynamics Special Purpose Corp.
Common Stock |
A - Award | 112.519 | 123.252 | 1.048,35 | ||||
2022-06-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
A - Award | 47.059 | 209.756 | 28,92 | ||||
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 89.005 | 3,34 | ||||
2022-06-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.052 | 86.132 | 2,44 | ||||
2022-05-31 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 17.123 | 84.080 | 25,57 | 1,46 | 25.000 | 122.757 | |
2022-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 499.762 | 499.762 | |||||
2022-05-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.873 | 5.747 | -33,33 | ||||
2022-05-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.053 | 4.105 | -33,34 | ||||
2022-05-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 66.957 | 4,48 | ||||
2022-05-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.053 | 64.084 | 3,31 | ||||
2022-04-22 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 30.000 | 4.720.012 | 0,64 | 1,44 | 43.329 | 6.817.113 | |
2022-04-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.874 | 8.620 | -25,00 | ||||
2022-04-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.052 | 6.158 | -24,99 | ||||
2022-04-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.874 | 62.031 | 4,86 | ||||
2022-04-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.052 | 59.157 | 3,59 | ||||
2022-03-21 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 0 | -100,00 | ||||
2022-03-21 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 162.697 | 0,95 | ||||
2022-03-21 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 50.000 | 50.000 | |||||
2022-03-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 26.178 | 161.162 | 19,39 | 1,91 | 50.000 | 307.819 | |
2022-03-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.873 | 11.494 | -20,00 | ||||
2022-03-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.053 | 8.210 | -20,00 | ||||
2022-03-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 57.105 | 5,30 | ||||
2022-03-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.053 | 54.232 | 3,93 | ||||
2022-02-23 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.534 | 1.535 | -49,98 | ||||
2022-02-23 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.534 | 134.984 | 1,15 | ||||
2022-01-31 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.873 | 14.367 | -16,66 | ||||
2022-01-31 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.052 | 10.263 | -16,66 | ||||
2022-01-31 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 52.179 | 5,83 | ||||
2022-01-31 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.052 | 49.306 | 4,34 | ||||
2022-01-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 3.069 | -33,34 | ||||
2022-01-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 133.450 | 1,16 | ||||
2022-01-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.874 | 17.240 | -14,29 | ||||
2022-01-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.052 | 12.315 | -14,28 | ||||
2022-01-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.874 | 47.254 | 6,48 | ||||
2022-01-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.052 | 44.380 | 4,85 | ||||
2021-12-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 4.604 | -25,00 | ||||
2021-12-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 131.915 | 1,18 | ||||
2021-12-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.873 | 20.114 | -12,50 | ||||
2021-12-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.053 | 14.367 | -12,50 | ||||
2021-12-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 42.328 | 7,28 | ||||
2021-12-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.053 | 39.455 | 5,49 | ||||
2021-11-22 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.534 | 6.139 | -19,99 | ||||
2021-11-22 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.534 | 130.380 | 1,19 | ||||
2021-11-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.873 | 22.987 | -11,11 | ||||
2021-11-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.052 | 16.420 | -11,11 | ||||
2021-11-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.873 | 37.402 | 8,32 | ||||
2021-11-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.052 | 34.529 | 6,32 | ||||
2021-10-26 | 3 | OHAA |
Opy Acquisition Corp. I
Common Stock |
0 | ||||||||
2021-10-19 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 7.673 | -16,67 | ||||
2021-10-19 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 128.846 | 1,21 | ||||
2021-10-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.874 | 25.860 | -10,00 | ||||
2021-10-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -2.053 | 18.472 | -10,00 | ||||
2021-10-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.874 | 32.477 | 9,71 | ||||
2021-10-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 2.053 | 29.603 | 7,45 | ||||
2021-09-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 9.208 | -14,29 | ||||
2021-09-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 127.311 | 1,22 | ||||
2021-09-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -5.746 | 28.734 | -16,66 | ||||
2021-09-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
M - Exercise | -4.104 | 20.525 | -16,66 | ||||
2021-09-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 5.746 | 27.550 | 26,35 | ||||
2021-09-03 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
M - Exercise | 4.104 | 21.804 | 23,19 | ||||
2021-08-19 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.534 | 10.743 | -12,49 | ||||
2021-08-19 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.534 | 125.776 | 1,23 | ||||
2021-07-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 12.277 | -11,11 | ||||
2021-07-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 124.242 | 1,25 | ||||
2021-07-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
A - Award | 34.480 | 34.480 | |||||
2021-07-02 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Restricted Stock Units |
A - Award | 24.629 | 24.629 | |||||
2021-06-21 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 13.812 | -10,00 | ||||
2021-06-21 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 122.707 | 1,27 | ||||
2021-05-25 | 3 | DYNS |
Dynamics Special Purpose Corp.
Class A common stock |
10.733 | ||||||||
2021-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.534 | 15.347 | -9,09 | ||||
2021-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.534 | 121.172 | 1,28 | ||||
2021-05-13 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 27.919 | 27.919 | |||||
2021-04-20 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
M - Exercise | -1.535 | 16.881 | -8,34 | ||||
2021-04-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
M - Exercise | 1.535 | 119.638 | 1,30 | ||||
2021-03-22 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 120.000 | 120.000 | |||||
2021-03-22 |
|
4 | AXLA |
Axcella Health Inc.
Restricted Stock Units |
A - Award | 18.416 | 18.416 | |||||
2021-02-16 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
S - Sale | X | -26.704 | 4.690.012 | -0,57 | 14,93 | -398.560 | 69.998.898 |
2021-02-10 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
S - Sale | X | -7.404 | 4.716.716 | -0,16 | 14,79 | -109.525 | 69.772.965 |
2021-02-10 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
S - Sale | X | -2.100 | 4.724.120 | -0,04 | 14,83 | -31.146 | 70.065.313 |
2021-02-10 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
S - Sale | X | -89.233 | 4.726.220 | -1,85 | 14,88 | -1.328.117 | 70.343.641 |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 200 | 17.700 | 1,14 | 7,02 | 1.404 | 124.254 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 500 | 17.500 | 2,94 | 6,98 | 3.490 | 122.150 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.000 | 17.000 | 6,25 | 6,91 | 6.910 | 117.470 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 800 | 16.000 | 5,26 | 7,16 | 5.728 | 114.560 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 4.970 | 15.200 | 48,58 | 6,49 | 32.255 | 98.648 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 30 | 10.230 | 0,29 | 6,45 | 194 | 65.984 | |
2020-12-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 200 | 10.200 | 2,00 | 6,40 | 1.280 | 65.280 | |
2020-11-04 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 1.071 | 6.397 | 20,10 | 105,07 | 112.500 | 672.182 | |
2020-10-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 44.743 | 44.743 | |||||
2020-10-14 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 59.395 | 59.395 | |||||
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.000 | 10.000 | 11,11 | 4,58 | 4.580 | 45.800 | |
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.000 | 9.000 | 12,50 | 4,48 | 4.480 | 40.320 | |
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.000 | 8.000 | 14,29 | 4,47 | 4.470 | 35.760 | |
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 2.752 | 7.000 | 64,78 | 4,46 | 12.274 | 31.220 | |
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 3.248 | 4.248 | 324,80 | 4,40 | 14.291 | 18.691 | |
2020-09-01 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Common Stock |
P - Purchase | 1.000 | 1.000 | 4,34 | 4.340 | 4.340 | ||
2020-06-08 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 6.800 | 6.800 | |||||
2020-05-26 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 115.771 | 115.771 | |||||
2020-05-22 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 65.000 | 65.000 | |||||
2020-05-22 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
2020-05-20 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 50.000 | 118.103 | 73,42 | 4,75 | 237.500 | 560.989 | |
2020-05-08 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 1 | 5.255 | 0,02 | 131,31 | 107 | 690.096 | |
2020-05-08 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 1.047 | 1.047 | |||||
2020-05-05 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 997 | 5.255 | 23,42 | ||||
2020-05-05 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
D - Sale to Issuer | -997 | 0 | -100,00 | ||||
2020-03-19 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 4.815.453 | 0,10 | 3,76 | 18.800 | 18.106.103 | |
2020-03-17 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 4.810.453 | 0,10 | 4,00 | 20.000 | 19.241.812 | |
2020-03-17 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
P - Purchase | 5.000 | 4.805.453 | 0,10 | 3,82 | 19.100 | 18.356.830 | |
2020-03-02 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.005 | 68.103 | 3,03 | 3,75 | 7.519 | 255.386 | |
2020-03-02 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 12.800 | 66.098 | 24,02 | 3,65 | 46.720 | 241.258 | |
2019-12-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.005 | 53.298 | 1,92 | 3,91 | 3.930 | 208.395 | |
2019-12-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 14.000 | 52.293 | 36,56 | 3,55 | 49.700 | 185.640 | |
2019-12-02 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.005 | 53.298 | 1,92 | 3,91 | 3.930 | 208.395 | |
2019-12-02 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 14.000 | 52.293 | 36,56 | 3,55 | 49.700 | 185.640 | |
2019-11-05 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 462 | 4.203 | 12,35 | 121,74 | 56.250 | 511.721 | |
2019-09-17 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 75.000 | 75.000 | |||||
2019-09-17 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 75.000 | 75.000 | |||||
2019-08-23 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 65.000 | 65.000 | |||||
2019-08-23 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 35.000 | 35.000 | |||||
2019-08-05 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 2.849 | 38.293 | 8,04 | 7,04 | 20.057 | 269.583 | |
2019-08-05 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 4.092 | 35.444 | 13,05 | 6,98 | 28.562 | 247.399 | |
2019-07-18 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.000 | 31.352 | 3,29 | 7,55 | 7.550 | 236.708 | |
2019-07-10 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.322 | 30.352 | 4,55 | 8,07 | 10.669 | 244.941 | |
2019-07-10 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 4.200 | 29.030 | 16,92 | 8,24 | 34.608 | 239.207 | |
2019-07-10 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 274 | 24.830 | 1,12 | 9,00 | 2.466 | 223.470 | |
2019-07-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 56 | 19.056 | 0,29 | 8,99 | 503 | 171.313 | |
2019-07-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 3.500 | 19.000 | 22,58 | 8,76 | 30.678 | 166.535 | |
2019-07-03 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 1.000 | 15.500 | 6,90 | 8,74 | 8.735 | 135.392 | |
2019-07-01 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 5.400 | 20.000 | 36,99 | 10,04 | 54.216 | 200.800 | |
2019-07-01 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 100 | 14.600 | 0,69 | 9,15 | 915 | 133.590 | |
2019-06-27 |
|
4 | AXLA |
Axcella Health Inc.
Common Stock |
P - Purchase | 14.500 | 14.500 | 9,57 | 138.765 | 138.765 | ||
2019-06-13 |
|
4 | EVLO |
Evelo Biosciences, Inc.
Stock Option (Right to Buy) |
A - Award | 15.690 | 15.690 | |||||
2019-05-28 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 39.094 | 39.094 | |||||
2019-05-24 |
|
4 | AXLA |
Axcella Health Inc.
Stock Option (Right to Buy) |
A - Award | 11.000 | 11.000 | |||||
2019-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 874 | 3.699 | 30,93 | ||||
2019-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
D - Sale to Issuer | -874 | 0 | -100,00 | ||||
2019-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 997 | 997 | |||||
2019-02-14 |
|
5 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
G - Gift | 180.000 | 180.000 | |||||
2019-02-14 |
|
5 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
G - Gift | -180.000 | 4.800.453 | -3,61 | ||||
2019-02-14 |
|
5 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 48 | 2.795 | 1,75 | ||||
2018-07-18 |
|
4 | RUBY |
Rubius Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 1.902.977 | 1.902.977 | |||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
9.960.906 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
9.960.906 | ||||||||
2018-07-17 | 3 | RUBY |
Rubius Therapeutics, Inc.
Common Stock |
9.960.906 | ||||||||
2018-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 874 | 874 | |||||
2018-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 882 | 2.747 | 47,29 | ||||
2018-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
D - Sale to Issuer | -882 | 0 | -100,00 | ||||
2018-02-02 |
|
5 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 25 | 1.865 | 1,36 | ||||
2017-05-05 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 882 | 882 | |||||
2017-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 938 | 1.840 | 103,99 | ||||
2017-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
D - Sale to Issuer | -938 | 0 | -100,00 | ||||
2017-02-07 |
|
5 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 3 | 583 | 0,52 | ||||
2017-02-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 319 | 899 | 55,00 | ||||
2017-02-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
D - Sale to Issuer | -319 | 0 | -100,00 | ||||
2016-12-06 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 160 | 160 | 118,46 | 18.954 | 18.954 | ||
2016-11-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Stock Equivalent Unit |
A - Award | 420 | 420 | 133,84 | 56.213 | 56.213 | ||
2016-05-03 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 938 | 938 | |||||
2016-02-02 |
|
4 | IFF |
INTERNATIONAL FLAVORS & FRAGRANCES INC
Restricted Stock Units |
A - Award | 319 | 319 |